Navigation Links
China Biologic Products Gains Financial Support from Shandong Provincial Government on the Improvement of Production Facilities
Date:1/14/2008

TAI'AN CITY, Shandong, China, Jan. 14 /Xinhua-PRNewswire-FirstCall/ -- China Biologic Products, Inc. (Pink sheets: CBPO) ("China Biologic" or the "Company"), one of the leading manufacturers of plasma-based pharmaceutical products in the People's Republic of China ("China" or the "PRC"), today announced that it was granted a RMB1.5 million (approximately US$0.2 million) award by the Shandong Provincial Government for use in the improvement of its plasma production facilities in accordance with Shandong's "Double Hundred Project" initiative.

The Double Hundred Project initiative was launched in January 2006 by Shandong Province, in response to China's Eleventh Five-year Development Plan. Through the Double Hundred Project, Shandong set up a special fund to develop what it identified as one hundred key products and one hundred key technology innovation centers in the province. The project provides, among other things, policy and financial support as well as quantitative government assessment to develop the chosen one hundred key products into eventually becoming, within five years, among China's top three products in terms of production capacity in their respective industries. Recognition of a product by the project also results in brand recognition for a manufacturer within Shandong Province and throughout China.

The Company's grant award was preceded by the Company's formal acceptance into the Double Hundred Project by the Shandong Economic and Trade Committee on December 21, 2007.

"We consider this award from the government as a strong endorsement of our continuous efforts in research and development and of our achievements in upgrading our production facilities to develop more technologically advanced plasma based products," said Mr. Stanley Wong, CEO of China Biologic. "We expect that support from the project will provide us with a competitive edge for our manufacturing technology and our products."

About China Biologic Products, Inc.

China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's principal products are human albumin and immunoglobulin products that are used mainly to increase blood volume and for disease prevention and treatment.

Safe Harbor Statement

This press release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc., and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding the ability of the Company to achieve its commercial objectives, the business strategy, plans and objectives of the Company and its subsidiaries and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Company Contact:

Mr. Stanley Wong

CEO

China Biologic Products, Inc.

Tel: +86-538-6202608

Email: IR@ctbb.com.cn

Investor Relations Contact:

Mr. Crocker Coulson

President

CCG Elite Investor Relations

Tel: +1-646-213-1915 (NY office)

Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... companies dedicated to collaboratively developing improved chemistry, manufacturing and control technologies for ... online UHPLC, with robust, probe-based sampling. , Online liquid chromatography analysis ...
(Date:12/2/2016)... Dec. 2, 2016 /PRNewswire/ - bioLytical Laboratories, a world leader in rapid infectious disease ... Kenya,s Pharmaceutical Association members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ... ... , , ... Kenya Pharmaceutical Association (KPA) to introduce the INSTI HIV Self Test to 350 pharmacy ...
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
(Date:11/30/2016)... -- Tempus, a technology company focused on supporting physicians ... Center have partnered to better determine which patients ... based on next generation genomic and transcriptomic sequencing. ... collaboration, Tempus will provide sequencing and analysis of ... Penn. Utilizing next-generation sequencing, machine learning and bioinformatics, ...
Breaking Biology Technology:
(Date:11/17/2016)... Global Market Watch: Primarily supported by ... Banks and Academics) market is to witness a value of ... the highest Compounded Annual Growth Rate (CAGR) of 10.75% is ... analysis period 2014-2020. North America is ... Europe at 9.56% respectively. Report ...
(Date:11/15/2016)... -- Research and Markets has announced the addition of ... to their offering. ... The global bioinformatics ... USD 6.21 Billion in 2016, growing at a CAGR of 21.1% ... market is driven by the growing demand for nucleic acid and ...
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
Breaking Biology News(10 mins):